Original Article Compressed glyceryl monostearate based biodegradable implant of Gentamicin using melt granulation technique: In vitro evaluation & biocompatibility in animals Ashish Y. Pawar a, *, Kiran B. Erande a , Deepak D. Sonawane a , Vikas R. Asawale a , Yogesh S. Harak a , Deelip V. Derle b a Department of Pharmaceutics, MGV’s Pharmacy College, Panchavati, Nashik 422 003, Maharashtra, India b Department of Pharmaceutics, N.D.M.V.P’s College of Pharmacy, Gangapur Road, Nashik 422 002, Maharashtra, India article info Article history: Received 17 January 2013 Accepted 14 March 2013 Keywords: Gentamicin Implant Melt granulation Osteomyelitis Histocompatible abstract Objective: Osteomyelitis is a multibacterial bone infection which is still remains challenging and difficult to treat, despite of advances in antibiotics and new operative techniques. Present study aims at formulating Gentamicin implants in treatment of Osteomyelitis & other bone infections using glyceryl monostearate (GMS) matrices as a carrier. Methods: Gentamicin implants were prepared by using combination of glyceryl mono- stearate and poly ethylene glycol as hydrophobic biodegradable sustained release matrices along with different percentage of Sorbitol and Tween80 as erosion enhancers. Several formulations were prepared (K1eK7) by melt granulation followed by compression to form disc shaped implants. The prepared formulations were evaluated for different in vitro pa- rameters & optimized formulation was subjected to in vivo study. Results & discussion: Formulation K4 shows excellent cumulative drug release profile and it does not completely lose its physical shape even after 28 days thus this formulation conclude to be optimum formulation among the all GMS based implant formulations. Also optimized GMS based implant does not show any severe signs of inflammation and other foreign body reactions in laboratory animals, thus it was concluded that GMS based implant have acceptable biological compatibility even after 28 days. Conclusion: Therefore from this study it is proved that, the glyceryl monostearate based implants have potential to retard the drug release for more than five weeks in the treat- ment of osteomyelitis & bone infections. Copyright ª 2013, JPR Solutions; Published by Reed Elsevier India Pvt. Ltd. All rights reserved. 1. Introduction Osteomyelitis is a historic infection which still remains chal- lenging and difficult to treat, despite of advances in antibiotics and new operative techniques. Osteomyelitis is also known as progressive infection of bone or bone marrow and surround- ing tissues. 1,2 It is caused by variety of microorganisms but Staphylococcus aureus (80e85%) is the major organisms * Corresponding author. Tel.: þ91 9823481646. E-mail address: pawarashish23@gmail.com (A.Y. Pawar). Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/dit drug invention today 5 (2013) 39 e49 0975-7619/$ e see front matter Copyright ª 2013, JPR Solutions; Published by Reed Elsevier India Pvt. Ltd. All rights reserved. http://dx.doi.org/10.1016/j.dit.2013.03.006